On February 21, 2023 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported the formation of its Breast Cancer Clinical Advisory Board comprising preeminent experts across the breast cancer research and clinical development fields (Press release, Anixa Biosciences, FEB 21, 2023, View Source [SID1234627486]). This represents another milestone as the Company prepares for the next steps in advancing its breast cancer vaccine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are privileged to have the opportunity to work with leading experts in the breast cancer field who have extensive experience in and understanding of the clinical development of treatments and preventions for breast cancer," stated Amit Kumar, Ph.D., Chairman and CEO of Anixa. "Working with these individuals will better equip Anixa to plan and prepare for future clinical trials of our breast cancer vaccine."
The Anixa Biosciences Breast Cancer Clinical Advisory Board is comprised of the following members:
Arnold Baskies, MD, FACS, is a specialist in surgical oncology and general surgery, affiliated with Virtua Health Systems. He is former Chairman of the National Board of Directors of the American Cancer Society and current Chair of the society’s Global Cancer Control Advisory Council. He is a member of the Global Breast Cancer Initiative, World Health Organization (WHO), and Director and Scientific Advisory Board Member of Anixa Biosciences.
G. Thomas Budd, MD, FACP, is a specialist in breast cancer and the principal investigator of the Cleveland Clinic and Anixa partnered Phase 1 trial of the Breast Cancer Vaccine. He is Professor of Medicine in the Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Cancer Center, and Professor in the Department of Medicine, School of Medicine and member of the Immune Oncology Program, Case Comprehensive Cancer Center. He is a member of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and the American Association for Cancer Research (AACR) (Free AACR Whitepaper).
Lisa H. Butterfield, Ph.D., is a tenured academician (UCLA and University of Pittsburgh) and former President of the Society of Immunotherapy of Cancer (SITC) (Free SITC Whitepaper). She is an Adjunct Professor of Microbiology and Immunology at UCSF, a member of the UCSF Helen Diller Family Comprehensive Cancer Center, Cancer Immunotherapy, and core faculty at the Herbert Perkins Cellular Therapy and Transfusion Medicine Fellowship. She is a member of the AACR (Free AACR Whitepaper) Cancer Immunology Working Group Steering Committee, and a member and Chair of the U.S. Food and Drug Administration (FDA) Cellular, Tissues and Gene Therapies Advisory Committee.
Brian Czerniecki, MD, Ph.D., is the Chair and Senior Member in the Moffitt Cancer Center Department of Breast Oncology and a renowned surgeon and physician scientist investigating the development of vaccines for the prevention of breast cancer and other solid tumors. He is recognized nationally for his contribution to the development of sentinel lymph node mapping. He has published over 100 scientific articles and is the recipient of numerous grants for his research.
Brian Leyland-Jones, MBBS, MD, Ph.D., FACP, FRCPC, is a pre-eminent clinical trialist in oncology and the recipient of numerous awards. He is the Chief Medical Officer of AIM-HI Accelerator Fund, OTraces, and the N OF 1 Mission. In addition, he is a Scientific Advisory Board Member of the National Foundation for Cancer Research and NED Biosystems, Inc. He is the CSO of The Darwin Foundation, collectively devoted to the implementation of prevention and cure of malignancy globally, and Director Emeritus for the WIN (Worldwide Innovative Networking in personalized cancer medicine) Consortium.
Hope Rugo, MD, FASCO, is a leader and specialist in breast cancer research and recipient of numerous awards. She is Professor, Department of Medicine (Hematology/Oncology), and Director, Breast Oncology and Clinical Trials Education, at the UCSF Helen Diller Family Comprehensive Cancer Center. She is Co-chair of the Triple Negative Working Group, a member of the Translational Breast Cancer Research Consortium (TBCRC), Alliance Breast Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB), and a member of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper).
Pamela D. Garzone, Ph.D., Anixa’s Chief Development Officer, who recruited and will chair the Clinical Advisory Board stated, "We are looking forward to advice and guidance from the world’s foremost breast cancer thought leaders as we design and advance the clinical trials for our breast cancer vaccine."
About Anixa Bioscience’s Breast Cancer Vaccine
Anixa’s breast cancer vaccine, currently in Phase 1 trials, takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing. This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic’s Lerner Research Institute. Dr. Tuohy is named as inventor on the technology, which Cleveland Clinic exclusively licensed to Anixa Biosciences.